Emcure Pharmaceuticals Ltd on Thursday reported 40.76% jump in consolidated profit after tax at Rs 215 crore for the first quarter ended June 30, 2025 driven by robust performance of both domestic and international businesses.
The company had posted a profit after tax of Rs 153 crore in the corresponding period last fiscal, Emcure Pharmaceuticals said in a regulatory filing.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
Revenue from operations in the quarter under review stood at Rs 2,101 crore as against Rs 1,815 crore in the year-ago period. Total expenses were higher at Rs 1,809.98 crore as compared to Rs 1,630.81 crore.
International business revenue from operations was up 22.1% at Rs 1,106 crore in the first quarter as compared to Rs 906 crore in the corresponding period last fiscal, it added.
Similarly, domestic revenue from operations was at Rs 995 crore as against Rs 909 crore in the first quarter last fiscal, up 9.4%. It was led by strong performance in all key therapies and aided by new initiatives in derma and OTC.
Commenting on the performance, Emcure Pharmaceuticals CEO and Managing Director, Satish Mehta said, "We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets though in-licensing and in-house development." He further said, "The expanded Sanofi partnership positions us well in the fast growing metabolic segment." On the way forward, he said, "We also have a strong product pipeline for both our domestic and international markets which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins."
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.